Literature DB >> 10842327

Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation.

Y Liu1, A McKalip, B Herman.   

Abstract

We and others have previously reported that human papillomavirus (HPV)-16 E6 protein expression sensitizes certain cell types to apoptosis. To confirm that this sensitization occurred in HPV's natural host cells, and to explore the mechanism(s) of sensitization, we infected human keratinocytes (HKCs) with retroviruses containing HPV-6 E6, HPV-16 E6, HPV-16 E7, or HPV-16 E6/E7. Apoptosis was monitored by DNA fragmentation gel analysis and direct observation of nuclei in cells stained with DAPI. Exposure of HKCs to etoposide, cisplatin, mitomycin C (MMC), atractyloside, and sodium butyrate, resulted in a time and dose-dependent induction of apoptosis. Expression of HPV-16 E6 and HPV-16 E6/E7, but not HPV-6 E6 or HPV-16 E7, enhanced the sensitivity of HKCs to cisplatin-, etoposide- and MMC-, but not atractyloside- or sodium butyrate-induced apoptosis. Expression of both HPV-16 E6 and HPV-16 E6/E7 decreased, but did not abolish, p53 protein levels relative to normal HKCs, and resulted in cytoplasmic localization of wt p53. P53 induction occurred in HPV-16 E6 and HPV-16 E6/E7 expressing cells after exposure to cisplatin or MMC, though never to levels found in normal untreated HKCs. P21 levels were decreased in HPV-16 E6 and HPV-16 E6/E7 expressing HKCs, and no induction of p21 was seen in these cells following exposure to cisplatin or MMC. Caspase-3 activity was found to be elevated in HPV-16 E6-expressing HKCs following exposure to cisplatin and MMC as documented by fluorometric and Western Blot analysis. Expression of wt CrmA or treatment of HPV-16 E6 expressing HKCs with the caspase-3 inhibitor DEVD.fmk prevented HPV-16 E6-induced sensitization in HKCs. These results suggest that HPV-16 E6 and HPV-16 E6/E7 expression sensitizes HKCs to apoptosis caused by cisplatin, etoposide and MMC, but not atractyloside or sodium butyrate. The data also suggest that wt p53 and caspase-3 activity are required for HPV-16 E6 and HPV-16 E6/E7-induced sensitization of HKCs to DNA damaging agents. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842327

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents.

Authors:  Zhi-Guo Liu; Li-Na Zhao; Ying-Wang Liu; Ting-Ting Li; Dai-Ming Fan; Jason J Chen
Journal:  J Mol Biol       Date:  2007-09-18       Impact factor: 5.469

3.  p53 and hTERT determine sensitivity to viral apoptosis.

Authors:  Marie L Nguyen; Rachel M Kraft; Martine Aubert; Edward Goodwin; Daniel DiMaio; John A Blaho
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

4.  Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16.

Authors:  W Li; R A Anderson
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

5.  The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection.

Authors:  P García-López; M Coll; E Cervera; L Reyes-Vermot; M A Torres; G Abrego-Pérez; A I Hernández-Pájaro; G Castañeda-Hernandez; A Mohar-Betancourt; A Meneses
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

Review 6.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

7.  Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.

Authors:  B Pajares; L Perez-Villa; J M Trigo; M D Toledo; M Alvarez; B Jimenez; J A Medina; V de Luque; J M Jerez; E Alba
Journal:  Clin Transl Oncol       Date:  2013-11-06       Impact factor: 3.405

8.  Construction and detection of the tissue-specific pINV-HPV16 E6/7 vector.

Authors:  Hui Gao; Zhengfang Huang; Chenlong Shi; Houda Li
Journal:  Oncol Lett       Date:  2014-11-25       Impact factor: 2.967

9.  Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.

Authors:  Bella Pajares; Jose M Trigo; Maria D Toledo; Martina Álvarez; Carlos González-Hermoso; Antonio Rueda; Jose A Medina; Vanessa de Luque; Jose M Jerez; Emilio Alba
Journal:  BMC Cancer       Date:  2013-01-18       Impact factor: 4.430

10.  Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human Papilloma virus 16.

Authors:  Tamar Geiger; Alexander Levitzki
Journal:  PLoS One       Date:  2007-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.